Neel B Shah1, Beverly L Hersh2, Alex Kreger2, Aatif Sayeed2, Andrew G Bullock2, Scott D Rothenberger3, Brian Klatt4, Brian Hamlin5, Kenneth L Urish4,6,7,8. 1. Division of Infectious Disease, Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 2. School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Center for Research on Health Care Data Center, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 4. Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Bone and Joint Center, Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 6. Arthritis and Arthroplasty Design Group, Bone and Joint Center, Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 7. Department of Bioengineering, and Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania. 8. Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Total knee arthroplasty (TKA) periprosthetic joint infection (PJI) can be managed with debridement, antibiotic therapy, and implant retention (DAIR). Oral antibiotics can be used after DAIR for an extended time period to improve outcomes. The objective of this study was to compare DAIR failure rates and adverse events between an initial course of intravenous antibiotic therapy and the addition of extended treatment with oral antibiotics. METHODS: A multicenter observational study of patients diagnosed with a TKA PJI who underwent DAIR was performed. The primary outcome of interest was the failure rate derived from the survival time between the DAIR procedure and future treatment failure. RESULTS: One hundred eight patients met inclusion criteria; 47% (n = 51) received an extended course of oral antibiotics. These patients had a statistically significant lower failure rate compared to those who received only intravenous antibiotics (hazard ratio, 2.47; P = .009). Multivariable analysis demonstrated that extended antibiotics independently predicted treatment success, controlling for other variables. There was no significant difference in failure rates between an extended course of oral antibiotics less or more than 12 months (P = .23). No significant difference in the rates of adverse events was observed between patients who received an initial course of antibiotics alone and those who received a combination of initial and extended antibiotic therapy (P = .59). CONCLUSIONS: Extending therapy with oral antibiotics had superior infection-free survival for TKA PJI managed with DAIR. There was no increase in adverse events, demonstrating safety. After 1 year, there appears to be no significant benefit associated with continued antibiotic therapy. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND: Total knee arthroplasty (TKA) periprosthetic joint infection (PJI) can be managed with debridement, antibiotic therapy, and implant retention (DAIR). Oral antibiotics can be used after DAIR for an extended time period to improve outcomes. The objective of this study was to compare DAIR failure rates and adverse events between an initial course of intravenous antibiotic therapy and the addition of extended treatment with oral antibiotics. METHODS: A multicenter observational study of patients diagnosed with a TKA PJI who underwent DAIR was performed. The primary outcome of interest was the failure rate derived from the survival time between the DAIR procedure and future treatment failure. RESULTS: One hundred eight patients met inclusion criteria; 47% (n = 51) received an extended course of oral antibiotics. These patients had a statistically significant lower failure rate compared to those who received only intravenous antibiotics (hazard ratio, 2.47; P = .009). Multivariable analysis demonstrated that extended antibiotics independently predicted treatment success, controlling for other variables. There was no significant difference in failure rates between an extended course of oral antibiotics less or more than 12 months (P = .23). No significant difference in the rates of adverse events was observed between patients who received an initial course of antibiotics alone and those who received a combination of initial and extended antibiotic therapy (P = .59). CONCLUSIONS: Extending therapy with oral antibiotics had superior infection-free survival for TKA PJI managed with DAIR. There was no increase in adverse events, demonstrating safety. After 1 year, there appears to be no significant benefit associated with continued antibiotic therapy. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Authors: Kenneth L Urish; Peter W DeMuth; Brian W Kwan; David W Craft; Dongzhu Ma; Hani Haider; Rocky S Tuan; Thomas K Wood; Charles M Davis Journal: Clin Orthop Relat Res Date: 2016-07 Impact factor: 4.176
Authors: Hélène Chaussade; Ilker Uçkay; Albert Vuagnat; Jérôme Druon; Guillaume Gras; Philippe Rosset; Benjamin A Lipsky; Louis Bernard Journal: Int J Infect Dis Date: 2017-08-10 Impact factor: 3.623
Authors: Douglas R Osmon; Elie F Berbari; Anthony R Berendt; Daniel Lew; Werner Zimmerli; James M Steckelberg; Nalini Rao; Arlen Hanssen; Walter R Wilson Journal: Clin Infect Dis Date: 2012-12-06 Impact factor: 9.079
Authors: Benjamin Zmistowski; Joseph A Karam; Joel B Durinka; David S Casper; Javad Parvizi Journal: J Bone Joint Surg Am Date: 2013-12-18 Impact factor: 5.284
Authors: Kenneth L Urish; Andrew G Bullock; Alexander M Kreger; Neel B Shah; Kwonho Jeong; Scott D Rothenberger Journal: J Arthroplasty Date: 2017-11-21 Impact factor: 4.757
Authors: C E Marculescu; E F Berbari; A D Hanssen; J M Steckelberg; S W Harmsen; J N Mandrekar; D R Osmon Journal: Clin Infect Dis Date: 2006-01-05 Impact factor: 9.079
Authors: Georgios K Triantafyllopoulos; Lazaros A Poultsides; Wei Zhang; Peter K Sculco; Yan Ma; Thomas P Sculco Journal: J Arthroplasty Date: 2014-10-25 Impact factor: 4.757
Authors: Chuan Kong Koh; Irene Zeng; Saiprassad Ravi; Mark Zhu; Kelly G Vince; Simon W Young Journal: Clin Orthop Relat Res Date: 2017-06-01 Impact factor: 4.176
Authors: Marcelo B P Siqueira; Anas Saleh; Alison K Klika; Colin O'Rourke; Steven Schmitt; Carlos A Higuera; Wael K Barsoum Journal: J Bone Joint Surg Am Date: 2015-08-05 Impact factor: 5.284
Authors: Jesse W P Kuiper; Stan J Cj Vos; Rachid Saouti; Diederik A Vergroesen; Harm C A Graat; Yvette J Debets-Ossenkopp; Edgar J G Peters; Peter A Nolte Journal: Acta Orthop Date: 2013-07-12 Impact factor: 3.717
Authors: Nicholas P Drain; Valerie C Gobao; Dominique M Bertolini; Clair Smith; Neel B Shah; Scott D Rothenberger; Malcolm E Dombrowski; Michael J O'Malley; Brian A Klatt; Brian R Hamlin; Kenneth L Urish Journal: J Arthroplasty Date: 2020-03-04 Impact factor: 4.757
Authors: Jason Zlotnicki; Alexandra Gabrielli; Kenneth L Urish; Kimberly M Brothers Journal: Orthop Clin North Am Date: 2021-02-10 Impact factor: 2.472
Authors: T David Tarity; William Xiang; Christopher W Jones; Ioannis Gkiatas; Allina Nocon; Nicolas A Selemon; Alberto Carli; Peter K Sculco Journal: Arthroplast Today Date: 2022-03-02
Authors: Don Bambino Geno Tai; Elie F Berbari; Gina A Suh; Brian D Lahr; Matthew P Abdel; Aaron J Tande Journal: Open Forum Infect Dis Date: 2022-07-25 Impact factor: 4.423